



Press release

SHL Telemedicine Ltd. to Continue Engagement of Chairman of the Board, Co-CEOs and Chief Technology Officer on terms to be Agreed, Subject to Shareholder Approval

Tel Aviv/Zurich, 8 August 2014 - SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN, OTCPK: SMDCY), a leading provider and developer of advanced personal telemedicine solutions (the "Company"), today announced that both Company and each of its Chairman of the Board, Elon Shalev, Co-CEOs, Yariv and Erez Alroy, and Chief Technology Officer, Irit Alroy (all members of the Alroy Group), wishes to continue his or her engagement with the Company on terms to be agreed upon and approved by the requisite corporate, including shareholder, approval.

Pursuant to the provisions of the Israeli Companies Law, the above persons' engagement terms require approval by the Company's organs, amongst which the general meeting of shareholders, once every three (3) years. The engagement terms were last approved on August 10, 2011.

It is clarified that in the event shareholder approval is not obtained in the shareholder meeting planned in October 2014, (the exact date to be fixed by the Board of Directors once the meeting is convened, and announced pursuant to law), Company shall be deemed to have given each of the above persons a notice of termination (with applicable notice periods, as the case may be) as of August 10, 2014.

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. The Company operates in Israel, Germany, India and the United States in one business segment, Telemedicine services. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and has an ADR program listed over-the counter; Symbol: SMDCY. For more information please visit our web site at www.shl-telemedicine.com.

Contacts:

| | |
|--|--|
| Erez Alroy | Martin Meier-Pfister |
| Co-CEO | IRF Communications |
| P:+972 3 5612212, | P: +41 43 244 81 40 |
| ereza@shl-telemedicine.com | shl@irfcom.ch |

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.